Oculis (OCS) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed Oculis (OCS) over the past year, gaining 57.1% versus a loss of 63.3%. Over five years, OCS leads with a -27.3% price change compared with -32.5% for OVID. Ovid Therapeutics is the larger company by market cap ($415.2 million vs $393.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCS | OVID |
|---|---|---|
| Share price | $7.06 | $2.20 |
| Market cap | $393.35M | $415.21M |
| 1-day change | -5.11% | -5.98% |
| YTD return | -64.65% | +34.97% |
| 1-year return | -63.34% | +57.14% |
| 5-year return | -27.29% | -32.52% |
| EPS (TTM) | $-1.69 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $7.25M |
| Revenue growth (YoY) | — | +1181.27% |
| Net income (latest FY) | — | $-17.41M |
| Operating margin | — | -585.20% |
| Net margin | — | -240.13% |
| 52-week high | $34.48 | $3.11 |
| 52-week low | $6.78 | $1.26 |
| Distance from 52-week high | -79.52% | -29.15% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +407.79% | +179.55% |
| Average volume | 272.83K | 1.98M |
| Shares outstanding | 55.72M | 188.73M |
| Employees | 60 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed OCS by 120.5 percentage points over the past year.
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
OCS vs OVID FAQ
Which is bigger, Oculis or Ovid Therapeutics?
Ovid Therapeutics (OVID) is larger, with a market capitalization of $415.21M compared with $393.35M for Oculis (OCS).
Which stock has performed better over the past year, OCS or OVID?
OVID returned +57.14% over the past 12 months, compared with -63.34% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are Oculis and Ovid Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.